Navigation Links
Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2013
Date:10/23/2013

were $138 million, up 6 percent from the year-ago quarter, and revenues for fiscal year 2013 were $546 million, up 11 percent from the prior fiscal year.  Compared to the corresponding periods in fiscal year 2012, X-Ray Products' fourth quarter gross orders rose 26 percent to $183 million, and fiscal year gross orders rose 15 percent to $585 million.  There was no material difference between gross and net orders for the X-ray business during the quarter or fiscal year.

"Our X-Ray Products business generated double digit order growth for the quarter and the fiscal year in both tubes and flat panels," Wilson said. "Our components are being designed into next-generation imaging equipment from several large manufacturers, and we appear to be gaining share in this market."

Other
The company's Other category, which is comprised of the Security and Inspection Products business, the Varian Particle Therapy business, and the Ginzton Technology Center, recorded fourth quarter revenues of $47 million versus $36 million in the year-ago quarter.  Revenues for fiscal year 2013 rose to $144 million from $125 million in fiscal year 2012.  The revenue gains for both the quarter and the fiscal year were driven by ongoing proton projects in San Diego, Saudi Arabia and Russia. 

Gross orders in the Other Category were $18 million for the fourth quarter and $86 million for the full fiscal year 2013, down $130 million from the prior year when the company booked two proton orders totaling over $120 million.  There was no material difference between gross and net orders for the Other category.

The company finished the fiscal year with $1.1 billion in cash and cash equivalents and $506 million of debt. Cash flow from operations was $155 million for the quarter and $455 million for the fiscal year.  During the fourth quarter, the company spent $135 million to repurchase 1.9 million shares of common stock. 

Outloo
'/>"/>

SOURCE Varian Medical Systems
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Varian Medical Systems Schedules Fiscal Year End Review for Investors in New York
2. Varians Calypso Tumor Tracking System Used in Lung, Stomach and Prostate Cancer Treatments at Leading European Cancer Center
3. Varian and Siemens to Showcase Collaborative Offerings at 2013 ASTRO Meeting in Atlanta
4. CIVCOs Protura and Varian Integration Keeps Motion Management Clearly on Target at ASTRO 2013
5. Varian Medical Systems Publishes 2013 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
6. Varian Medical Systems Schedules Investor Meeting at ASTRO in Atlanta
7. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
8. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2013
9. Supreme Court Ruling Today Allows DNATraits to Offer Low Cost BRCA Breast and Ovarian Cancer Gene Testing in U.S.
10. Varian Software Successfully Connected with Siemens Linear Accelerators
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ANDOVER, Mass. , Oct. 1, 2014 /PRNewswire/ ... ; AEX: PHIA) today announced its eCareCoordinator and ... the U.S. Food and Drug Administration (FDA). A ... of telehealth programs , eCareCoordinator and eCareCompanion are ... are the first clinical applications to be available ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
(Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
... Calif., Sept. 19, 2011 Amgen (NASDAQ: ... Drug Administration (FDA) approved two new indications for Prolia® ... women at high risk for fracture receiving adjuvant aromatase ... to increase bone mass in men at high risk ...
... Sept. 19, 2011 Boston Scientific Corporation (NYSE: ... a highly deliverable and ultra-low profile 0.014 inch balloon ... procedures below the knee.  The Company has begun marketing ... markets.   Boston Scientific developed the Coyote ...
Cached Medicine Technology:FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 2FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 3FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 4FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 5FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 6FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 7FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 8Boston Scientific Launches Coyote™ Balloon Catheter 2Boston Scientific Launches Coyote™ Balloon Catheter 3Boston Scientific Launches Coyote™ Balloon Catheter 4
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... four months of hormonal therapy before and with ... by as much as eight yearsespecially the development ... with potentially aggressive prostate cancer. This neoadjuvant hormonal ... developing bone metastases avoid long-term hormonal therapy later ...
... immune cells seems to halt the cells typical job ... study by Johns Hopkins researchers suggests. The findings ... ranging from annoying bouts of hay fever to deadly ... his colleagues at the Johns Hopkins Asthma and Allergy ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... 2008) Athanasios Zavras began receiving messages from distraught ... meds to bone death in the jaw. A number ... these drugs to postpone dental work, fearing that procedures ... when Zavras, an associate professor in the Harvard School ...
... (ACP) has received a Commonwealth Fund grant of nearly $225,000 ... The grant, part of the Commonwealth Funds Patient-Centered Primary ... in November. ACP committed matching funds late in 2007. ... goal is to put the needs of the patient first. ...
... use of opioid drugs to relieve severe pain, black ... to receive these pain-relievers in emergency rooms, according to ... for more than 150,000 pain-related visits to U.S. hospitals ... of whites received opioid drugs compared with only 23 ...
Cached Medicine News:Health News:Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years 2Health News:Protein a possible key to allergy and asthma control 2Health News:Protein a possible key to allergy and asthma control 3Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2Health News:American College of Physicians receives grant to study cost of patient-centered medical home 2Health News:Blacks, Hispanics less likely to get strong pain drugs in emergency rooms 2
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
Coronary angiographic catheter...
Leksell Neuro Generator is a complete system for stereotactic lesioning, pain treatment, stimulation and bipolar coagulation. It features a radio frequency (RF) energy source with sophisticated, inte...
Medicine Products: